AMPRENAVIR

Description

AMPRENAVIR · CAS 161814-49-9 · C25H35N3O6S. UNII 5S0W860XNR. Solubility: In water, 40 mg/l @ 25 °C; Solubility: 4.91e-02 g/L; Vapor Pressure: 9.9X10-18 mm Hg @ 25 °C /Estimated/.

Identification

CAS Registry Number	161814-49-9
PubChem CID	65016
Molecular formula	C25H35N3O6S
IUPAC name	[(3S)-oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate
UNII (FDA)	5S0W860XNR

Computed Descriptors

Molecular Weight	505.6
XLogP3	2.9
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	12
Exact Mass	505.22465702
Monoisotopic Mass	505.22465702
Topological Polar Surface Area	140
Heavy Atom Count	35
Formal Charge	0

Physical & Chemical Properties

Solubility	In water, 40 mg/l @ 25 °C
Solubility	4.91e-02 g/L
Vapor Pressure	9.9X10-18 mm Hg @ 25 °C /Estimated/
LogP	log Kow = 2.2 @ 25 °C /Estimated/

Physical description & handling notes

• Solid
• Henry's Law constant = 1.6X10-23 atm-cu m/mol @ 25 °C /Estimated/
• Hydroxyl radical reaction rate constant = 1.1X10-10 cu cm/molec sec @ 25 °C /Estimated/
• Oral: Capsules, liquid-filled, 50 mg, Agenerase (with propylene glycol 19 mg and vitamin E 36 units), GlaxoSmithKline; 150 mg, Agenerase (with propylene glycol and vitamin E 109 units), GlaxoSmithKline.Solution: 15 mg/ml, Agenerase (with propylene glycol 550 mg/ml, and vitamin E 46 units/ml), GlaxoSmithKline

GHS Hazard Classification

Reported hazard statements	H351 (100%), H361 (100%), H412 (100%)

Documented Uses

• For the treatment of HIV-1 infection in combination with other antiretroviral agents.
• Preparation: ... R.D. Tung et al, US 5585397 (1994, 1996 both to Vertex)
• Amprenavir is indicated in combination with other antiretroviral agents in the treatment of HIV-1 infection. /Included in US product labeling/
• Amprenavir is a human immunodeficiency virus (HIV)-protease inhibitor. The use of amprenavir for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in combination with other antiretrovirals is based on analyses of plasma HIV-RNA levels and CD4 cell counts in controlled studies of up to 24 weeks duration. Results from controlled trials evaluating the long-term suppression of HIV-RNA or disease progression with amprenavir have not yet been obtained.
• Patients being treated with amprenavir oral solution should be closely monitored for propylene glycol associated side effects including hemolysis, hyperosmolality, lactic acidosis, renal toxicity, seizures, stupor, and tachycardia.
• The pharmacokinetics of amprenavir do not differ between females and males or between Blacks and non-Blacks. However, amprenavir oral solution contains a large amount of propylene glycol and because Asians, Eskimos, Native Americans, and women have a decreased ability to metabolize this compound, they may have an increased risk of developing propylene glycol-associated side effects.

Synonyms

amprenavir; 161814-49-9; Agenerase; VX-478; Prozei; 141W94; KVX-478; Vertex VX478; VX 478; 5S0W860XNR; CHEBI:40050; J05AE05; Tetrahydro-3-furyl N-(3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxypropyl)carbamate; KVX 478; DTXSID5046061; Amprenavirum

Frequently Asked Questions

What are the CAS number and molecular formula of AMPRENAVIR?

CAS 161814-49-9; molecular formula C25H35N3O6S; molecular weight — g/mol.

What other names is AMPRENAVIR known by?

amprenavir, 161814-49-9, Agenerase, VX-478, Prozei, 141W94.

Is AMPRENAVIR classified as hazardous?

Hazard statements reported: H351, H361, H412.

What are the key physical properties of AMPRENAVIR?

Solubility: In water, 40 mg/l @ 25 °C; Solubility: 4.91e-02 g/L; Vapor Pressure: 9.9X10-18 mm Hg @ 25 °C /Estimated/; LogP: log Kow = 2.2 @ 25 °C /Estimated/.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.